FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Stack Library

Natural GH Pulse

GH Optimizationbeginner

90

synergy

90
Share
Peptides

2

Avg Daily mcg

300

Level

beginner

Added

May 17, 2026

Overview

The Natural GH Pulse stack combines a growth hormone releasing hormone (GHRH) analog with a selective growth hormone secretagogue to produce amplified, pulsatile GH release that mimics the body''s natural rhythm. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF) is a truncated and modified analog of endogenous GHRH that stimulates the pituitary to produce growth hormone. Its short half-life (approximately 30 minutes) means it generates discrete GH pulses rather than sustained elevation, preserving the body''s natural feedback mechanisms. Ipamorelin is a pentapeptide that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering GH release without significantly affecting cortisol, prolactin, or ACTH levels — making it the cleanest growth hormone secretagogue available. Unlike older secretagogues such as GHRP-6, Ipamorelin does not stimulate appetite or raise cortisol, making it suitable for long-term use. The synergy between CJC-1295 (no DAC) and Ipamorelin is well-documented: GHRH analogs and ghrelin-mimetics act through different receptors on the same pituitary cells, producing an amplified GH pulse approximately 3-5x greater than either peptide alone. This phenomenon is called the "GH synergy effect" and has been demonstrated in human clinical studies. The combined pulse mimics the magnitude of youthful GH secretion while maintaining pulsatility, which is critical for avoiding GH receptor desensitization. Benefits include improved sleep architecture (deeper slow-wave sleep), enhanced recovery from exercise, modest fat reduction, and improved skin quality over 3-6 months of consistent use.

Dosing Protocol

CJC-1295 (no DAC)

Every day· subcutaneous

Read more about CJC-1295 (no DAC) →

100 mcg

per dose

Ipamorelin

Every day· subcutaneous

Read more about Ipamorelin →

200 mcg

per dose

Goals & Evidence

Growth hormoneAnti-agingFat lossSleep qualityRecovery
Evidence tier:Human RCT

Warnings

  • CJC-1295 and Ipamorelin both remain on the FDA Category 2 restricted-compounding list as of July 2026. Do not use with active cancer.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.